Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 2Phase 3 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 2768Carcinoma, Non-Small-Cell Lung 2267Prostatic Neoplasms 1427Colorectal Neoplasms 1295Neoplasms 1260Multiple Myeloma 1086Lung Neoplasms 1050Neoplasm Metastasis 995Leukemia, Myeloid, Acute 985Lymphoma 900Melanoma 864Pancreatic Neoplasms 819Ovarian Neoplasms 805Carcinoma, Hepatocellular 782Stomach Neoplasms 754Recurrence 753Leukemia 733Lymphoma, Non-Hodgkin 685Leukemia, Lymphocytic, Chronic, B-Cell 665Squamous Cell Carcinoma of Head and Neck 618Lymphoma, Large B-Cell, Diffuse 617Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Head and Neck Neoplasms 599Brain Neoplasms 593Carcinoma, Renal Cell 587Glioblastoma 573Rectal Neoplasms 565Sarcoma 523Myelodysplastic Syndromes 522Lymphoma, Follicular 516

Interventions

Injections 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Metastatic Castration-resistant Prostate Cancer (mCRPC) × Clear all
NCT06241846 2025-08-27

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

MediLink Therapeutics (Suzhou) Co., Ltd.

Phase 2 Recruiting
100 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04862091 2022-03-04

Comparative Study of Abiraterone Acetate Tablets (I) or ZYTIGA® in Patients With Metastatic Castration-resistant Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
69 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡